Safety & Immunogenicity of Booster SARS-CoV-2 Vaccine (Vero Cell)
A Phase II Non-Randomized Open Labelled Clinical Trial to Evaluate the Safety & Immunogenicity of SARS-COV-2 Vaccine (Vero Cell) Inactivated as A Booster Dose
Sponsor: PT. Kimia Farma (Persero) Tbk
A PHASE2 clinical study on COVID-19, this trial is ongoing. The trial is conducted by PT. Kimia Farma (Persero) Tbk and has accumulated 5 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
5 versions recorded-
Oct 2024 — Present [monthly]
Unknown PHASE2
Status: Recruiting → Unknown
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Dec 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- PT. Kimia Farma (Persero) Tbk
For direct contact, visit the study record on ClinicalTrials.gov .